Neurotransmitter uncaging, especially that of glutamate, has been used to study synaptic function for over 30 years. One limitation of caged glutamate probes is the blockade of GABA-A receptor function. This problem comes to the fore when the probes are applied at the high concentrations required for effective 2-photon photolysis. To mitigate such problems one could improve the photochemical properties of caging chromophores and/or remove receptor blockade. We show that addition of a dicarboxylate unit to the widely used MNI-Glu reduced the off-target effects by about 50-70%. When the same strategy was applied to an electron rich 2-(p-phenyl-onitrophenyl)-propyl (PNPP) cage, the pharmacological improvements were not as significant as for MNI. Finally, we used very extensive biological testing of the PNPP-caged Glu (more than 250 uncaging currents at single dendritic spines) to show that nitro-biphenyl caging chromophores have a 2-photon uncaging efficacy similar to that of MNI-Glu.Photochemically protected neurotransmitters offer physiologists a powerful means of controlling important aspects of chemical and electrical signaling in cells from the central nervous system [1][2][3] . Such optical probes, called caged compounds, initially used the orthonitrobenzyl [4] and ortho-nitroveratryl [5] chromophores developed, respectively, by Baltrop and Patchornik. Whilst such chromophores have proved the most widely used of all photochemical protecting groups in both chemistry and biology [6][7][8] , benzyl ester derivatives of biomolecules such as Glu and GABA have some predictable (e.g. hydrolysis at physiological pH), and some unpredictable weaknesses (e.g. GABA-A antagonism) in the context of synaptic physiology [3] .Several studies have sought to address these issues. For example, in 1999 Corrie and coworkers showed that a 7-nitroindolinyl-caged Glu [9] is very stable at physiological pH (i.e. 7.4). Subsequently several studies published by the Corrie/Ogden and Ellis-Davies/Kasai